Skip to main content
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Inc. — Investor Relations & Filings

Ticker · PMN ISIN · CA74346M1095 LEI · 5299007HZF79F9IAXI53 US Professional, scientific and technical activities
Open in API
Filings indexed 333 across all filing types
Latest filing 2025-07-22 Regulatory Filings
Country CA Canada
Listing US PMN

About ProMIS Neurosciences Inc.

https://www.promisneurosciences.com/

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on the discovery and development of selective antibody therapeutics for neurodegenerative and other misfolded protein diseases. The company leverages a proprietary technology platform to design and generate antibodies that selectively target toxic oligomers, which are key drivers of diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and multiple system atrophy (MSA). Its lead product candidate, PMN310, is in clinical development for Alzheimer's disease. The company's approach aims to provide effective treatments while potentially reducing side effects associated with less specific therapies.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes termination of a material definitive agreement (an At The Market Offering Agreement) and other events such as FDA Fast Track Designation and clinical trial updates. There are no financial statements or detailed financial analysis present, and the document is relatively short (4594 characters). This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement reporting significant corporate events but not a full financial report or other specific filing type.
2025-07-22 English
8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by ProMIS Neurosciences Inc. It discusses a Nasdaq deficiency letter regarding the company's failure to maintain the minimum bid price for continued listing on the Nasdaq Capital Market. The report details the compliance periods granted by Nasdaq and the company's plans to regain compliance, including the possibility of a reverse stock split. There are no financial statements or detailed financial data presented; rather, it is an announcement of a regulatory event related to listing compliance and potential delisting. This fits the definition of a Delisting Announcement (DLST) as it concerns official notice and discussion about the risk of delisting due to non-compliance with listing rules.
2025-07-07 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-07-02 English
PRIMARY DOCUMENT
Director's Dealing
2025-06-16 English
PRIMARY DOCUMENT
Director's Dealing
2025-06-16 English
PRIMARY DOCUMENT
Director's Dealing
2025-06-16 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.